The Role of Cytoreductive Nephrectomy in Patients With Synchronous Metastases From RCC

Brian Rini, MD, associate professor, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, discusses the role of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma (RCC).

Clinical Pearls

Brian Rini, MD, associate professor, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, discusses the role of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma (RCC).

  • About 20 years ago, subsequent cytoreductive nephrectomy and interferon demonstrated a survival advantage in patients with metastatic RCC
  • Researchers and oncologists question whether cytoreductive nephrectomy should remain a part of the treatment approach in this space
  • Several retrospective analyses have supported the current role of cytoreductive nephrectomy
  • Patient selection bias prevents too much weight being placed on these retrospective studies
  • Two prospective studies are underway, though it will be some time before those read out